tiprankstipranks
Trending News
More News >

Kate Haviland Insider Profile

4 Followers
Kate Haviland, CEO, Director at Blueprint Medicines, holds 0.00 shares in Blueprint Medicines (Ticker: BPMC), holds ― shares in Fulcrum Therapeutics (Ticker: FULC), holds ― shares in Bicara Therapeutics Inc. (Ticker: BCAX).
tipranks
Kate Haviland

Kate Haviland
Blueprint Medicines (BPMC)
CEO, Director

Ranked #88,836 out of 106,487 Corporate Insiders

Profitable Transactions

67%
4 out of 6 Profitable Transactions

Average Return

-23.80%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

Kate Haviland does not currently own shares as a corporate insider.
A breakdown of Kate Haviland's holdings

Insider Roles

Fulcrum Therapeutics
(FULC)
Director
Bicara Therapeutics Inc.
(BCAX)
Director
Roles that Kate Haviland holds in companies

Most Profitable Insider Trade

Stock:
Blueprint Medicines
(BPMC)
Rating:Informative Sell
Date:Mar 05, 2021 - Mar 05, 2022
Return:+40.50%
The most profitable trade made by Kate Haviland

Kate Haviland's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
BPMC
Blueprint Medicines
Jul 21, 2025
Uninformative Buy
$0.00
Fulcrum Therapeutics
Director
Bicara Therapeutics Inc.
Director
List of latest transactions for each holding click on a transaction to see Kate Haviland's performance on stock

Kate Haviland insider profile FAQ

What is the percentage of profitable transactions made by Kate Haviland?
The percentage of profitable transactions made by Kate Haviland is 67%.
    What is the average return per transaction made by Kate Haviland?
    The average return per transaction made by Kate Haviland is -23.80%.
      What stocks does Kate Haviland hold?
      Kate Haviland holds: BPMC, FULC, BCAX stocks.
        What was Kate Haviland’s latest transaction?
        Kate Haviland latest transaction was an Uninformative Buy of ―.
          What was Kate Haviland's most profitable transaction?
          Kate Haviland’s most profitable transaction was an Informative Sell of BPMC stock on March 5, 2021. The return on the trade was 40.50%.
            What is Kate Haviland's role in Blueprint Medicines?
            Kate Haviland's role in Blueprint Medicines is CEO, Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.